Vancouver, British Columbia – April 23, 2014 – Sirona Biochem Corp. (TSX-V: SBM.V OTCQX: SRBCF, Frankfurt: ZSB) ) is pleased to announce that its subsidiary, TFChem, has been selected for participation in the UBISTART Tour July 10-11, 2014 at the New York Academy of Sciences, New York City, New York USA. The UBISTART Tour, which combines innovation and scientific excellence in life sciences, encourages and rewards international partnerships between French and North American innovators within the pharmaceutical, biotechnology, medical technology, and healthcare industries. An international jury under the auspices of the Galien Foundation Board was responsible for the selection of TFChem and other French participants to the UBISTART Tour.
“Worldwide, the Prix Galien is regarded as the equivalent of the Nobel Prize in biopharmaceutical research,” comments Neil Belenkie, CEO of Sirona Biochem. “We are extremely proud to be recognized for inclusion in the UBISTART Tour by globally respected organizations such as the Galien Foundation and UBIFRANCE.”
About The UBISTART Program
On July 10, during the UBISTART Tour, the selected participating companies will have the opportunity to present their project(s), to learn about the projects of other companies and to meet with potential partners (either from companies or other individuals in the program).
The partnerships that arise from the UBISTART Tour will then have three months to develop and present their international project and apply to the UBISTART competition. The Galien Foundation Board, which includes several Nobel Laureates, will oversee the selection of the independent international jury who will be responsible each December for choosing and awarding the UBISTART Award to the most innovative and promising of the projects originating from the UBISTART Tour.
About The Galien Foundation
The Galien Foundation fosters, recognizes and rewards excellence in scientific innovation to improve the state of human health. Our vision is to be the catalyst for the development of the next generation of innovative treatment and technologies that will impact human health and save lives.
The Foundation oversees and directs activities in the USA for the Prix Galien, an international award that recognizes outstanding achievements in improving the human condition through the development of innovative therapies. The Prix Galien was created in 1970 in honor of Galen, the father of medical science and modern pharmacology. Worldwide, the Prix Galien is regarded as the equivalent of the Nobel Prize in biopharmaceutical research.
UBIFRANCE, the French Agency for International Business Development comes under the aegis of France’s Ministry for the Economy, Finance & Industry.
UBIFRANCE promotes technologies, products, services and know-how from France, and puts French-based professionals in contact with their international counterparts.
About Sirona Biochem
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.
Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For more information regarding this press release, contact:
Sirona Biochem Corp.
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem’s forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem’s business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.